Thermo Fisher Scientific INC Form 4 insider transactions

Lisa P. Britt, a Senior VP and Chief HR Officer at Thermo Fisher Scientific, reports an adjustment to a performance-based restricted stock unit award due to the company's relative total shareholder return.

Michael A. Boxer, SVP and General Counsel of Thermo Fisher Scientific, reports an adjustment to a performance-based restricted stock unit award due to the company's relative total shareholder return.

Executive Vice President Frederick M. Lowery of Thermo Fisher Scientific reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific's CEO, Marc Casper, reports the vesting of performance-based restricted stock units and the grant of stock options.

Lisa P. Britt, Sr. VP and Chief HR Officer of Thermo Fisher Scientific, reports acquisition of common stock and stock options.

Michael A. Boxer, SVP and General Counsel of Thermo Fisher Scientific, acquired 2,611 shares of common stock following the satisfaction of performance criteria related to a restricted stock unit award.

Executive Vice President & COO Michel Lagarde reports acquisition of stock and option awards from Thermo Fisher Scientific.

Executive Vice President Gianluca Pettiti reports acquisition of stock and option awards from Thermo Fisher Scientific.

Joseph R. Holmes, VP & Chief Accounting Officer of Thermo Fisher Scientific, reports acquisition of common stock and stock options.

Director Nelson Chai disclosed several transactions involving Thermo Fisher Scientific Inc. common stock, including purchases and sales, executed through a broker-managed account.

Executive Vice President Frederick M. Lowery reports acquisition of shares and options in Thermo Fisher Scientific following the satisfaction of performance criteria for a restricted stock unit award.

Executive Vice President Michael D. Shafer of Thermo Fisher Scientific reports the acquisition of common stock and stock options related to performance-based restricted stock units.

Stephen Williamson, Sr. VP and CFO of Thermo Fisher Scientific, reports the acquisition of common stock and stock options, including vesting of performance-based restricted stock units.

Director Karen S. Lynch reports acquisition and disposal of Thermo Fisher Scientific Inc. common stock.

Thermo Fisher Scientific's CEO, Marc Casper, reported the disposal of 2,750 shares of common stock on February 14, 2025.

Gianluca Pettiti, an Executive Vice President at Thermo Fisher Scientific, sold 300 shares of common stock at a price of $585.59 per share on February 4, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Stephen Williamson, CFO of Thermo Fisher Scientific, exercised stock options and sold shares of common stock on February 3rd and 4th, 2025, according to a recent SEC Form 4 filing.

Jennifer M. Johnson, a director at Thermo Fisher Scientific, acquired phantom stock units under the company's Deferred Compensation Plan for Directors.

Scott M. Sperling, a director of Thermo Fisher Scientific, reported the acquisition of stock units under the company's Deferred Compensation Plan for Directors.

Director R. Alexandra Keith reports acquisition of phantom stock units in Thermo Fisher Scientific through a deferred compensation plan.

Director Dion J. Weisler acquired 72.08 phantom stock units in Thermo Fisher Scientific through a deferred compensation plan.

Thermo Fisher Scientific's SVP and General Counsel, Michael A. Boxer, reported a gift of 190 common shares to a donor-advised fund.

Thermo Fisher Scientific's CEO, Marc Casper, sold a total of 20,449 shares of common stock over two days, December 2nd and 3rd, 2024, under a pre-arranged 10b5-1 trading plan.

Thermo Fisher Scientific's CEO, Marc Casper, executed multiple sales of common stock on November 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific's CEO, Marc Casper, executed multiple sales of company stock on November 6th and 7th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific's CEO, Marc Casper, exercised stock options and sold shares of common stock on November 1, 2024, according to a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific's CEO, Marc Casper, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Thermo Fisher Scientific's CEO, Marc Casper, exercised stock options and sold shares of common stock on October 28 and 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Michael A. Boxer, SVP and General Counsel of Thermo Fisher Scientific, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Executive Vice President Gianluca Pettiti of Thermo Fisher Scientific sold 300 shares of common stock at a price of $560.16 per share on October 25, 2024, according to a Form 4 filing.